Upregulation of connexin43 contributes to PX-12-induced oxidative cell death

[1]  Hui Zhang,et al.  A novel TXNIP-based mechanism for Cx43-mediated regulation of oxidative drug injury , 2015, Journal of cellular and molecular medicine.

[2]  W. Park,et al.  PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner , 2015, Tumor Biology.

[3]  S. Nakajima,et al.  Purinergic control of AMPK activation by ATP released through connexin 43 hemichannels – pivotal roles in hemichannel-mediated cell injury , 2014, Journal of Cell Science.

[4]  Wei Sun,et al.  5′-AMP-Activated Protein Kinase Attenuates Adriamycin-Induced Oxidative Podocyte Injury through Thioredoxin-Mediated Suppression of the Apoptosis Signal-Regulating Kinase 1–P38 Signaling Pathway , 2014, Molecular Pharmacology.

[5]  E. Gangoso,et al.  A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype , 2014, Cell Death and Disease.

[6]  W. Park,et al.  PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. , 2014, International journal of oncology.

[7]  M. El-Sabban,et al.  Context dependent reversion of tumor phenotype by connexin-43 expression in MDA-MB231 cells and MCF-7 cells: role of β-catenin/connexin43 association. , 2013, Experimental cell research.

[8]  A. Lavie,et al.  The Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis Offers Efficient Bystander Cell Killing for Suicide Gene Therapy of Cancer , 2013, PloS one.

[9]  T. Simmet,et al.  The thioredoxin system as a therapeutic target in human health and disease. , 2013, Antioxidants & redox signaling.

[10]  D. Roy,et al.  Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. , 2013, Biochimica et biophysica acta.

[11]  M. Kitamura,et al.  Connexin43 Hemichannel-Mediated Regulation of Connexin43 , 2013, PloS one.

[12]  Jae Yong Cho,et al.  Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. , 2012, World journal of gastroenterology.

[13]  M. Kitamura,et al.  NADPH oxidase-mediated upregulation of connexin43 contributes to podocyte injury. , 2012, Free radical biology & medicine.

[14]  T. Nguyen,et al.  Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth , 2012, PloS one.

[15]  M. Mesnil,et al.  Opposing roles of connexin43 in glioma progression. , 2012, Biochimica et biophysica acta.

[16]  R. Lothe,et al.  Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome , 2012, International journal of cancer.

[17]  L. Pham,et al.  Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma , 2012, Oncotarget.

[18]  J. Jassem,et al.  Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer , 2011, Drugs.

[19]  G. Weiss,et al.  A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy , 2012, Investigational New Drugs.

[20]  L. Foster,et al.  The gap junction protein Cx43 is involved in the bone-targeted metastatic behaviour of human prostate cancer cells , 2012, Clinical & Experimental Metastasis.

[21]  S. Pazzaglia,et al.  Role of connexin43 and ATP in long-range bystander radiation damage and oncogenesis in vivo , 2011, Oncogene.

[22]  Defeng Wu,et al.  Depletion of cytosolic or mitochondrial thioredoxin increases CYP2E1-induced oxidative stress via an ASK-1-JNK1 pathway in HepG2 cells. , 2011, Free radical biology & medicine.

[23]  Jean X. Jiang,et al.  Connexin43 hemichannels contribute to cadmium-induced oxidative stress and cell injury. , 2011, Antioxidants & redox signaling.

[24]  B. Tang,et al.  Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes , 2011, Medical oncology.

[25]  Andrew L. Harris,et al.  The Role of Gap Junction Communication and Oxidative Stress in the Propagation of Toxic Effects among High-Dose α-Particle-Irradiated Human Cells , 2011, Radiation research.

[26]  Yon Hui Kim,et al.  Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase , 2011, Cancer Chemotherapy and Pharmacology.

[27]  R. Zhao,et al.  Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. , 2010, Free radical biology & medicine.

[28]  C. Naus,et al.  Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells , 2010, Oncogene.

[29]  H. Masutani,et al.  Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. , 2010, Pharmacology & therapeutics.

[30]  M. Kitamura,et al.  Disruption of gap junctions attenuates aminoglycoside‐elicited renal tubular cell injury , 2010, British journal of pharmacology.

[31]  Mustapha Kandouz,et al.  Gap junctions and connexins as therapeutic targets in cancer , 2010, Expert opinion on therapeutic targets.

[32]  P. Crooks,et al.  A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. , 2010, Cancer research.

[33]  M. Kitamura,et al.  Gap junctions sensitize cancer cells to proteasome inhibitor MG132‐induced apoptosis , 2010, Cancer science.

[34]  T. Oite,et al.  Gap junctional intercellular communication in the juxtaglomerular apparatus. , 2009, American journal of physiology. Renal physiology.

[35]  K. Schalper,et al.  Opening of connexin 43 hemichannels is increased by lowering intracellular redox potential , 2007, Proceedings of the National Academy of Sciences.

[36]  S. Green,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[37]  G. Perez,et al.  Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor , 2006, Proceedings of the National Academy of Sciences.

[38]  Chiu-Hsieh Hsu,et al.  The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. , 2006, The Journal of laboratory and clinical medicine.

[39]  D. Frank,et al.  Single‐cell microinjection of cytochrome c can result in gap junction–mediated apoptotic cell death of bystander cells in head and neck cancer , 2005, Head & neck.

[40]  K. Tonissen,et al.  The thioredoxin-thioredoxin reductase system: over-expression in human cancer. , 2003, Anticancer research.

[41]  V. Krutovskikh,et al.  Gap junction intercellular communication propagates cell death in cancerous cells , 2002, Oncogene.

[42]  T. Takamatsu,et al.  Dominant-negative connexin43-EGFP inhibits calcium-transient synchronization of primary neonatal rat cardiomyocytes. , 2002, Experimental cell research.

[43]  J. Little,et al.  Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha -particle irradiated to nonirradiated cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Zocchi,et al.  Connexin 43 hemichannels mediate Ca2+‐regulated transmembrane NAD+ fluxes in intact cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  J. Trosko,et al.  Gap junctions and the regulation of cellular functions of stem cells during development and differentiation. , 2000, Methods.

[46]  V. Krutovskikh,et al.  Inhibition of intrinsic gap‐junction intercellular communication and enhancement of tumorigenicity of the rat bladder carcinoma cell line BC31 by a dominant‐negative connexin 43 mutant , 1998, Molecular carcinogenesis.

[47]  Steven Goldman,et al.  Gap-junction-mediated propagation and amplification of cell injury , 1998, Nature Neuroscience.

[48]  M. Kunkel,et al.  Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. , 1998, Biochemical pharmacology.